AGBL3 and non-Hodgkin lymphoma: Similarly, the exclusion of those testing positive for biomarkers of rheumatoid arthritis (RF-IgA, RF-IgM, or anti-CCP3) did not significantly alter the association between ANA and DLBCL (OR: 1.93, 95% CI: 1.11–3.36) or NHL (OR: 1.13, 95% CI: 0.80–1.61) risk.